politics

Merck and Moderna's mRNA cancer drug shows promise in melanoma trial

21 Ağustos 2026France 24

US drugmakers Merck and Moderna have announced a significant breakthrough in cancer treatment, with a personalized mRNA drug successfully reducing melanoma tumor recurrence in a large late-stage trial. This marks the first time mRNA technology has demonstrated positive results in such a substantial clinical setting.
Experts are optimistic about the implications for future cancer therapies.
The use of mRNA technology has gained momentum following the success of COVID-19 vaccines, prompting researchers to explore its applications in other diseases, including cancer. Melanoma, a particularly aggressive form of skin cancer, has been a focus for innovative treatments due to its high recurrence rates.
The success of this mRNA cancer drug could signal a new era in oncology, where personalized treatments become the norm. Given the historical challenges in developing effective cancer vaccines, this trial's results may pave the way for further research and investment in mRNA technologies, potentially transforming how…

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.